tsh biopharmoration Ltd Cash Flow Conversion Efficiency
tsh biopharmoration Ltd cash flow conversion efficiency. Based on the latest financial reports, tsh biopharmoration Ltd (8432) has a cash flow conversion efficiency ratio of 0.027x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$42.55 Million ≈ $1.34 Million USD) by net assets (NT$1.58 Billion ≈ $49.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of tsh biopharmoration Ltd (2017–2024)
Cash flow conversion efficiency of tsh biopharmoration Ltd from 2017 to 2024. This chart illustrates how tsh biopharmoration Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest tsh biopharmoration Ltd stock price today for real-time trading data and today's change.
tsh biopharmoration Ltd Cash Flow Conversion Ratio Explained
tsh biopharmoration Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
tsh biopharmoration Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of tsh biopharmoration Ltd ranked by their cash flow conversion efficiency. Also see how much is tsh biopharmoration Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avantium Holding BV
AS:AVTX
|
-0.112x |
|
CHANJET INFO.TECHN.-H-YC1
F:C7D
|
N/A |
|
Makarony Polskie S.A.
WAR:MAK
|
0.058x |
|
OM INFRA LIMITED
NSE:OMINFRAL
|
-0.050x |
|
Copartner Technology Corp
TW:3550
|
-0.091x |
|
Asian Insulators PCL
BK:AI
|
0.030x |
|
NFC Indonesia PT Tbk
JK:NFCX
|
0.035x |
|
Tenax Therapeutics Inc
NASDAQ:TENX
|
-0.125x |
Annual Cash Flow Conversion Efficiency for tsh biopharmoration Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of tsh biopharmoration Ltd from 2017 to 2024. Review 8432 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.62 Billion ≈ $51.13 Million |
NT$183.77 Million ≈ $5.79 Million |
0.113x | +323.28% |
| 2023-12-31 | NT$1.27 Billion ≈ $39.89 Million |
NT$33.87 Million ≈ $1.07 Million |
0.027x | -5.57% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.21 Million |
NT$34.35 Million ≈ $1.08 Million |
0.028x | -55.32% |
| 2021-12-31 | NT$1.08 Billion ≈ $34.14 Million |
NT$68.71 Million ≈ $2.16 Million |
0.063x | +515.07% |
| 2020-12-31 | NT$1.13 Billion ≈ $35.49 Million |
NT$11.61 Million ≈ $365.81K |
0.010x | -86.92% |
| 2019-12-31 | NT$1.12 Billion ≈ $35.44 Million |
NT$88.65 Million ≈ $2.79 Million |
0.079x | +41.06% |
| 2018-12-31 | NT$1.12 Billion ≈ $35.31 Million |
NT$62.62 Million ≈ $1.97 Million |
0.056x | -21.05% |
| 2017-12-31 | NT$1.15 Billion ≈ $36.12 Million |
NT$81.13 Million ≈ $2.56 Million |
0.071x | -- |
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more